Soligenix, Inc. (SNGX)
NASDAQ: SNGX · Real-Time Price · USD
2.430
0.00 (0.00%)
Feb 21, 2025, 4:00 PM EST - Market closed
Soligenix Employees
As of December 31, 2023, Soligenix had 15 total employees, including 13 full-time and 2 part-time employees. The number of employees did not change compared to the previous year.
Employees
15
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$24,279
Profits / Employee
-$473,274
Market Cap
6.10M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
SNGX News
- 18 days ago - Soligenix to Present at BIO CEO & Investor Conference - PRNewsWire
- 5 weeks ago - Soligenix to Present at Upcoming Investor Conferences - PRNewsWire
- 5 weeks ago - HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma - PRNewsWire
- 2 months ago - Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma - PRNewsWire
- 2 months ago - HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment - PRNewsWire
- 3 months ago - Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma - PRNewsWire
- 3 months ago - Soligenix to Present at November 21st Virtual Investor Summit Microcap Event - Accesswire
- 3 months ago - Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease - PRNewsWire